← Back to Search

TRPC5 Channel Inhibitor

GFB-887 for Diabetes

Phase 2
Waitlist Available
Research Sponsored by Goldfinch Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective in treating patients with kidney diseases caused by diabetes or other conditions.

Eligible Conditions
  • Diabetes
  • Nephrotic Syndrome
  • Glomerulonephritis
  • Urological Diseases
  • Nephritis
  • Endocrine Disorders
  • Kidney Disease
  • Diabetic Kidney Disease
  • Focal Segmental Glomerulosclerosis
  • Lipoid Nephrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage change in Urine Albumin-to-Creatinine Ratio (UACR)
Percentage change in Urine Protein-to-Creatinine Ratio (UPCR)
Secondary outcome measures
Incidence and severity of adverse events
Incidence of clinically significant changes in 12-lead electrocardiogram (ECG) parameters, vital signs measurements, and physical examinations
Incidence of clinically significant changes in laboratory parameters
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GFB-887 multiple ascending dose (MAD) activeExperimental Treatment1 Intervention
GFB-887 active once-daily dosing
Group II: GFB-887 MAD placeboPlacebo Group1 Intervention
GFB-887 placebo once-daily dosing
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GFB-887
2019
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

Goldfinch Bio, Inc.Lead Sponsor
4 Previous Clinical Trials
160 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Illinois
Texas
How old are they?
65+
18 - 65
What site did they apply to?
Adventist Health Partners
Clinical Advancement Center, PLLC
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Adventist Health Partners: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
2020. "A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04387448.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top